12:00 AM
 | 
Sep 30, 2013
 |  BioCentury  |  Finance

Locked up with Prosensa

Locked-up Prosensa VCs see gains sliced by drisapersen blowup in DMD

Investors in the last pre-IPO financing by Prosensa Holding N.V. (NASDAQ:RNA) have seen their prospective return slashed to 3x from better than 9x after this month's drisapersen blowup. That syndicate will have to hold its breath for a little longer, as the lockup period for that private round extends into November.

In January 2012, a group led by new investor New Enterprise Associates provided Prosensa with €22.7 million ($30.5 million) to help fund an ongoing Phase III trial of drisapersen to treat Duchenne muscular dystrophy (DMD).

Other participants included existing investors Abingworth; LSP-Life Sciences Partners; Gimv; Idinvest Partners;...

Read the full 471 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >